DIrector, Hamon Center for Therapeutic Oncology Research, Professor, Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center, Southwestern Medical School
Oncology
Dr. John D. Minna, MD
|
|
Give Review
John Minna is an expert in the field of Oncology. He studied medicine at Stanford University School of Medicine. Stanford University School of Medicine is one of the top medical schools in the US. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine He received 2 awards: "Fellow (FASCO)" and "Elected Member". John Minna is a published physician. He published 98 publications, including: 'Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?'
Publications
- From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.
- Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
- Nicotinic acetylcholine receptor expression in human airway correlates with Lung function.
- Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.
- Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
- Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
- A Systematic Analysis Reveals Heterogeneous Changes in the Endocytic Activities of Cancer Cells.
- NRF2 regulates serine biosynthesis in non-small cell Lung cancer.
- Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells.
- Cancer-specific production of N-acetylaspartate via NAT8L overexpression in non-small cell Lung cancer and its potential as a circulating biomarker.
- Multi-institutional oncogenic driver mutation analysis in Lung adenocarcinoma: The Lung Cancer Mutation Consortium experience.
- Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5.
- Genetic mutation of p53 and suppression of the miR-17~92 cluster are synthetic lethal in non-small cell Lung cancer due to upregulation of vitamin D signaling.
- Inflammation-related genetic variants predict toxicity following definitive radiotherapy for Lung cancer.
- On comparing heterogeneity across biomarkers.
- ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine Lung cancers.
- Clinicopathologic features and outcomes of patients with Lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
- Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
- A search for novel cancer/testis antigens in Lung cancer identifies VCX/Y genes expanding the repertoire of potential immunotherapeutic targets.
- Essential role of aldehyde dehydrogenase 1A3 (ALDH1A3) for the maintenance of non-small cell Lung cancer stem cells is associated with the STAT3 pathway.
- Loss of miR-125a expression in a model of K-ras-dependent pulmonary premalignancy.
- Using multiplexed assays of oncogenic drivers in Lung cancers to select targeted drugs.
- VEGF/VEGFR-2 upregulates EZH2 expression in Lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
- Branching morphogenesis of immortalized human bronchial epithelial cells in three-dimensional culture.
- Inflammation-related Genetic Variations and Survival for Advanced Non-Small Cell Lung Cancer Receiving First-line Chemotherapy.
- NeuroD1 mediates nicotine-induced migration and invasion via regulation of the nicotinic acetylcholine receptor subunits in a subset of neural and neuroendocrine carci...
- Comparison between concurrent and sequential chemoradiation for non-small cell Lung cancer in vitro.
- A Reevaluation of CD22 Expression in Human Lung Cancer.
- Adaptive prediction model in prospective molecular-signature-based clinical studies.
- IGFBP2/FAK Pathway Is Causally Associated with Dasatinib Resistance in Non-Small Cell Lung Cancer Cells.
- A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell Lung cancer pathogenesis.
- Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells.
- Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell Lung cancer.
- miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in Lung cancer.
- Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell Lung cancer.
- EGFR-Mediated Beclin 1 Phosphorylation in Autophagy Suppression, Tumor Progression, and Tumor Chemoresistance.
- Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer.
- Precision Medicine for Cancer Patients: Lessons Learned and the Path Forward.
- KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in Lung cancer.
- Genome-wide association study of genetic predictors of overall survival for non-small cell Lung cancer in never smokers.
- NeuroD1 regulates survival and migration of neuroendocrine Lung carcinomas via signaling molecules TrkB and NCAM.
- MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients.
- Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention.
- GWAS Meets TCGA to Illuminate Mechanisms of Cancer Predisposition.
- A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer Patients.
- An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhi...
- Defining molecular and cellular responses after low and high linear energy transfer radiations to develop biomarkers of carcinogenic risk or therapeutic outcome.
- Predictors of survival in never-smokers with non-small cell Lung cancer: a large-scale, two-phase genetic study.
- Global evaluation of Eph receptors and ephrins in Lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
- miR-337-3p and Its Targets STAT3 and RAP1A Modulate Taxane Sensitivity in Non-Small Cell Lung Cancers.
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome.
- Probe mapping across multiple microarray platforms.
- Molecular biology of Lung cancer: clinical implications.
- Transient but Not Stable ZEB1 Knockdown Dramatically Inhibits Growth of Malignant Pleural Mesothelioma Cells.
- SMAC Mimetic (JP1201) Sensitizes Non-Small Cell Lung Cancers to Multiple Chemotherapy Agents in an IAP-Dependent but TNF-?-Independent Manner.
- Targeted therapies for Lung cancer: clinical experience and novel agents.
- How do we safely get people to stop smoking?
- Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts.
- From Mice and Men to Earth and Space: Joint NASA-NCI Workshop on Lung Cancer Risk Resulting from Space and Terrestrial Radiation.
- Title Mechanistic Contribution of Ubiquitous 15-Lipoxygenase-1 Expression Loss in Cancer Cells to Terminal Cell Differentiation Evasion.
- Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non-Small-Cell Lung Cancer Patients.
- Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy.
- Oral iloprost improves endobronchial dysplasia in former smokers.
- STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17.
- Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell Lung cancer.
- Pivotal role of epithelial cell adhesion molecule in the survival of Lung cancer cells.
- Genome-Wide Association Study of Survival in Non-Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy.
- Sporadic breast Cancer patients' germline DNA exhibit an AT-rich microsatellite signature.
- Irreparable complex DNA double-strand breaks induce chromosome breakage in organotypic three-dimensional human Lung epithelial cell culture.
- A five-gene and corresponding protein signature for stage-I Lung adenocarcinoma prognosis.
- Knockdown of oncogenic KRAS in non-small cell Lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
- Evolving concepts in Lung carcinogenesis.
- Multipotent capacity of immortalized human bronchial epithelial cells.
- ALK inhibition for non-small cell Lung cancer: from discovery to therapy in record time.
- Aldehyde dehydrogenase activity selects for Lung adenocarcinoma stem cells dependent on notch signaling.
- Proteomic profiling identifies pathways dysregulated in non-small cell Lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
- Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.
- hnRNP L regulates the tumorigenic capacity of Lung cancer xenografts in mice via caspase-9 pre-mRNA processing.
- Non-small-cell Lung cancer mRNA expression signature predicting response to adjuvant chemotherapy.
- National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection...
- Lung cancer cell lines as tools for biomedical discovery and research.
- Steroid receptor coactivator-3 expression in Lung cancer and its role in the regulation of cancer cell survival and proliferation.
- Nrf2 and Keap1 abnormalities in non-small cell Lung carcinoma and association with clinicopathologic features.
- Tumor oncogenotypes and Lung cancer stem cell identity.
- Met activation in non-small cell Lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.
- Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in Lung squamous cell carcinoma.
- An orthotopic Lung tumor model for image-guided microirradiation in rats.
- Radiogenomics predicting tumor responses to radiotherapy in Lung cancer.
- Overcoming Cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression.
- A catalog of genes homozygously deleted in human Lung cancer and the candidacy of PTPRD as a tumor suppressor gene.
- Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic Cancer.
- MRI-visible micellar nanomedicine for targeted drug delivery to Lung cancer cells.
- Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the Lung.
- Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell Lung cancer.
- Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell Lung cancer in vitro and in vivo.
- Nuclear receptor expression defines a set of prognostic biomarkers for Lung cancer.
- Amplification of chromosomal segment 4q12 in non-small cell Lung cancer.
Schools
Stanford University School Of Medicine
Massachusetts General Hospital
Conditions Treated
- Lung Cancer
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Fellow (FASCO)
- Elected Member
Education
-
Massachusetts General Hospital -
Stanford University School of Medicine
Hospital
-
University of Texas Southwestern Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Yull E. Arriaga, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James K. Willson Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos Taboada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura F. Defina, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sophie W. Sun, MD |
|
|
Dr. Shifeng Mao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos H. Becerra, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Dennis H. Birenbaum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward J. Pearson, MD |
|
|
Dr. Cesar A. Santa-Maria, MD |